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ABSTRACT
An apparatus for analyzing the chemical composition of
light source onto the tissue and detectors for detecting
light re?ected by the tissue. The light source transmits
an incident beam having a wavelength ranging from
1000 to 2500 nm. A compound parabolic concentrator

(CPC) is connected to a distal end of the ?ber optic
probe to focus or concentrate the wavelengths of light
simultaneously and in parallel on a particular spot of
tissue. Alternatively, an inverted, substantially conical
re?ector is positioned to scatter the incident light across

the tissue. The method includes the steps of (1) focusing
light onto the tissue to be analyzed; (2) detecting light
re?ected by the tissue; and (3) analyzing the resulting
spectra across the full wavelength of the originally
focused light. A color image is then produced for subse

quent study.
8 Claims, 5 Drawing Sheets
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APPARATUS AND METHOD FOR MULTIPLE
WAVELENGTH OF TISSUE

.
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the drugs prescribed to treat lesions have serious side
effects.
Still another object is to provide a method and appa
ratus wherein infrared radiation of a wavelength range

This invention was made with government support
under NSF RII-86l0671 and NIH BRSG S07 RR05857

spanning substantially 1000-2500 nm and, more prefera
bly, 1500-2100 nm is simultaneously focused onto the

09 awarded by The National Science Foundation and
National Institute of Health, respectively. The govern

arterial endothelium under study. The re?ected infrared
radiation is then detected and analyzed at high speed to
not only identify lesions but also evaluate the progres

ment has certain rights in the invention.
This application is a continuation-in-part of US. pa

tent application Ser. No. 07/695,104, ?led May 3, 1991
now abandoned.

‘TECHNICAL FIELD
The present invention relates generally to medical

sion of disease and effectiveness of treatment.

Additional objects, advantages and other novel fea
tures of the invention will be set forth in part in the

description that follows and in part will become appar
ent to those skilled in the art upon examination of the

following or may be learned with the practice of the

research and diagnostics and, more particularly, to a

invention. The objects and advantages of the invention

method and apparatus adapted to produce spectra that
are indicative of the chemical composition of tissue and

may be realized and obtained by means of the instru

mentalities and combinations particularly pointed out in

in a more particular application, the inner walls of arter
the appended claims.
ies in vivo.
20
To achieve the foregoing and other objects, and in
accordance with the purposes of the present invention
BACKGROUND OF THE INVENTION
as described herein, an improved apparatus is provided
A number of techniques have been utilized in the past
for analyzing tissue including arterial lesions. The appa
to make constituent identi?cations in atherosclerotic
ratus may not only be utilized for in vitro analysis but
lesions. These techniques include HPLC, NMR chemi 25 also, advantageously may be utilized for in vivo analy
cal-shift imaging and immunocytochemistry. Atheroma
sis. The apparatus comprises alight source for transmit
recognition has been performed by other techniques
ting simultaneously and in parallel an incident beam of
including duplex ultrasound and pneumoplethysmogra
light of a wavelength range from 1000 to 2500 nm and
phy. Atheroma classi?cation has been made by micro
more preferably from 1500 to 2100 nm. A ?ber optic
scopic and histologic examinations. Additionally, spa
probe is operatively connected to the light source. A
tial pro?ling has been accomplished by chemical analy
light directing or focusing mechanism is mounted to the
sis, enzymatic assays and immuno?uorescence tech
distal end of the probe. The focusing mechanism may

niques.

comprise a compound parabolic concentrator (CPC)
While all of these different techniques and technolo
that may, for example, be formed from plastic and in
gies are useful in qualitatively analyzing atherosclerotic 35 clude a polished aluminum lining. The CPC is similar to
lesions and plaques in vitro, it should be appreciated
those designed for use for solar power concentration.

that new technologies used for treating atherosclerotic
lesions and plaques require a reliable method of in vivo
lesion and plaque recognition to be most effective. A
need therefore exists for a reliable apparatus and
method for the chemical examination of arterial endo
thelium and, more particularly, for analyzing the com

The CPC is adapted to compress the incident beam
from the transmitting ?ber optic onto a small spot on

the tissue surface undergoing analysis. Additionally, the
apparatus includes detectors, such as lead sul?de detec

tors, for detecting the scattered light from the artery
surface or other tissue being analyzed.
position of atherosclerotic lesions and plaques in living
In an alternative embodiment, the light directing
tissue.
mechanism comprises an inverted, substantially conical
45 re?ector developed from both ellipsoids of rotation and
SUMMARY 0F THE INVENTION

Accordingly, it is a primary object of the present
invention to provide a method and apparatus for analyz

paraboloids of rotation. This re?ector serves to direct
the incident beam from the transmitting optic ?ber over

the tissue undergoing analysis. Additionally, light re

ing tissue and particularly arterial tissue and the lesions

?ected by the tissue is directed or focused into receiving

and plaques associated therewith in a manner overcom

optic ?bers so as to allow for better detection and

ing the above-described limitations and disadvantages
of the prior art.

hence, chemical analysis of the tissue.

1 Another object of the present invention is to provide
an apparatus and method that may not only be used in in

The apparatus further includes means for high speed
parallel analyzing of the spectra re?ected from the tis
sue and producing color images thereof. Such a means

vitro analysis but is also adapted for in vivo analysis. 55 may, for example, comprise a supercomputer, such as
available at the University of Kentucky, and appropri
Advantageously, such an apparatus and method may be
utilized to not only localize lesions but to evaluate the
ate software such as the copyrighted Best Algorithm
progression of disease and the effectiveness of treat
software program developed by co-inventor, Robert A.
ment. More particularly, by permitting the actual
Lodder. Further, the ?ber optic probe of the apparatus
growth of lesions as well as the effectiveness of treat
is preferably adapted for introduction into a patient to
thereby allow in vivo analysis of tissue and particularly
ment to be studied as it is being administered, improved
treatment programs may be designed.
Yet another object of the present invention is to pro
vide a method and apparatus speci?cally adapted to

identify different lesion types to thereby allow physi
cians to prescribe appropriate drugs that are more likely
to provide effective treatment. This is a particularly
important consideration when it is realized that some of

the walls of arteries. This means may comprise any

catheter assembly appropriate for this purpose.
In accordance with a further aspect of the present
65 invention, a method of analyzing tissue including arte

rial lesions is provided. The method broadly includes
the steps of focusing light on the tissue to be analyzed
and detecting light re?ected by the tissue. As indicated

3
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FIG. 7 is a graphical representation summarizing the
process by which colors were assigned to pixels in the
black and white representations of the color images of
FIGS. 4 and 5; and

above, the light being focused is of a wavelength range
from 1000 to 2500 and more preferably 1500 to 2100 nm.

The method further includes a step of analyzing the

spectra from the tissue and producing color images
thereof. Advantageously, both the focusing and analyz
ing steps are performed to allow high speed data acqui
sition and analysis. Speci?cally light having a range of

tained utilizing the apparatus of the present invention.

wavelengths from 1000 to 2500 nm and more preferably
1500 to 2100 nm is simultaneously focused in parallel at

preferred embodiment of the invention an example of

all locations being analyzed. The analysis of the re

FIGS. Sa-c are NIR spectra of human apolipo

proteins apoA-I, apoA-II and apoB, respectively ob
Reference will now be made in detail to the present
0

?ected light is also completed simultaneously and in

which is illustrated in the accompanying drawing.
DETAILED DESCRIPTION OF THE
INVENTION
Reference is now made to the drawing ?gures show

parallel for all locations being analyzed over the same
range of wavelengths. As all tissues absorb light at all

these wavelengths, with different tissues absorbing only

ing the apparatus of the present invention for producing
and detecting spectra indicative of the chemical compo
broad band parallel approach is necessary to insure that
sition of tissue undergoing analysis. Two different em
no unusual tissue is missed during study. Hence, the
bodiments of the present invention are shown and de
analysis is more accurate and complete. Further, as the
scribed below and in the drawing ?gures. The ?rst
focusing and analysis are performed in parallel the com
plete study may still be completed in a suf?ciently short 20 embodiment shown in FIG. 1 is described below for use
in analyzing tissue in vitro. The second embodiment
time span to allow clinical utilization such as for arterial
shown
in FIG. 2 is described below for use in analyzing
angiography. In accordance with a further method of
tissue and, more particularly, arterial endothelium, in
analyzing arterial endothelium in vivo utilizing a ?ber
optic probe, the method includes the initial step of intro- ' vivo. It should be appreciated, however, that the fol
25 lowing detailed descriptions are being presented for
ducing the probe into an artery of a patient.
purposes of illustration and explanation, and accord
Still other objects of the present invention will be
a little more at some wavelengths than others, this

ingly, the embodiments are not to be considered as

come apparent to those skilled in this art from the fol

being limited to the particular applications being de

lowing description wherein there is shown and de
scribed a preferred embodiment of this invention, sim
ply by way of illustration of one of the modes best

scribed.
FIG. 1 schematically shows one embodiment of the

apparatus 10 of the present invention. More particu
larly, the apparatus 10 includes a ?ber optic probe,
generally designated by reference numeral 12. The
probe 12 includes an integrating sphere 14 of a type

suited to carry out the invention. As it will be realized,

the invention is capable of other different embodiments
and its several details are capable of modi?cation in

various, obvious aspects all without departing from the
invention. Accordingly, the drawings and descriptions

known in the art and formed of any appropriate mate

rial. A compound parabolic concentrator (CPC) 18 is
mounted to the integrating sphere 14. The CPC 18
includes a main body member 20 formed from plastic
and a polished aluminum lining 22. As is known, the
CPC 18 also includes a central optical aperture 23
through which light is directed and focused. This aper

will be regarded as illustrative in nature and not as
restrictive.

BRIEF DESCRIPTION OF THE DRAWING

The accompanying drawing incorporated in and
forming a part of this speci?cation illustrates several
aspects of the present invention and together with this
description serves to explain the principles of the inven
tion. In the drawing:

ture preferably has a diameter between 0.64 and 0.84

45

FIG. 1 is a schematical representation of one embodi

ment of the apparatus of the present invention including
a compound parabolic concentrator for the analysis of

tissue;
FIG. 2 is a schematical representation of a second,

mm2 and more preferably of substantially 0.74 mmz.
A ?ber optic bundle 24 is rigidly mounted to and held
in an inlet port 26 in the integrating sphere 14, opposite
the CPC 18. The ?ber optic bundle 24 (transmitting
?ber optic) is operatively connected to a light source 30
(see FIG. 1). The light source 30 is particularly adapted
for generating a spectrum of light having a wavelength
range from 1000 to 2500 nm and, more preferably from

alternative embodiment of the present invention includ

1500 to 2100 nm. Such a light source 30 may, for exam

ing an inverted, substantially cone-shaped re?ector;

ple, be a tungsten-halogen lamp with wavelength selec
tion being accomplished utilizing a concave holo

FIG. 3 is a distal end view of the ?ber optic bundle

used in the apparatus of the present invention;

graphic diffraction grating.

FIG. 4 is a black and white representation of a color 55

An individual light detector 34 is mounted on the

photographic image showing the lipoprotein composi

wall of the integrating sphere 14. Any appropriate de

tion of a thoracic aorta incubated in Kreb’s physiolog

tector known in the-art may be utilized including a lead
sul?de detector and/or an indium antimonide detector

ical salt solution;
FIG. 5 is another black and white representation of a

color photographic image showing the lipoprotein

cooled with liquid nitrogen.

composition of a thoracic aorta incubated in Kreb’s

Light of from 1000 to 2500 nm and more preferably
of from 1500 to 2100 nm from the source 30 is directed

physiological salt solution that also contained low-den

simultaneously and in parallel along the transmitting

sity lipoprotein;

60

?ber optic bundle 24 to the ?ber optic probe 12. There
FIG. 6 is a graphical representation depicting the
the light from the source 30 is projected as an incident
spectral vector of the principal axis transformation ma 65 beam through the integrating sphere 14, the CPC 18 and
trix corresponding to the spectral change observed in
the aperture 23 onto a tissue sample T (note incident
the aorta specimens incubated in low-density lipopro
light beam depicted in full line by action arrows A). As
shown even scattered light of the incident beam is redi
tem;

5
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rected and is concentrated by the CPC 18 so as to be

tightly focused on a point P of the tissue sample T.

A signi?cant portion of the incident light projected
onto the point P of the tissue sample T is re?ected back
into the CPC 18 through the aperture 23. The scattered,
re?ected light is shown in dash line with reference to
action arrow B. As shown, the re?ected light is directed

tion that also contained low density lipoprotein

(LDL)(500 ug/mL).
The aortas were washed following incubation and

passed beneath the CPC 18 of the probe 12 while the
concentrator was held ?xed. A micropositioning stage

by the parabolic walls of the CPC 18 into the integrat
ing sphere 14. The integrating sphere 14 then directs the

was used to allow spectra to be collected along the axis
of the aorta when the aorta was opened to expose the
internal surface. Both specimens were scanned along a

re?ected light so that it falls upon the detector 34.
As shown the detector 34 is connected to a means 36

for analyzing the detected spectra and producing color

images thereof.‘ Speci?cally, the analysis is completed
over the full wavelength range of the incident light
directed upon the tissue. Thus, re?ected light having a 15
wavelength range between 1000 to 2500 nm and more

preferably 1500 to 2100 nm is analyzed simultaneously

and in parallel. Further, equal weighting is given to

6

bated for two hours in Kreb’s physiological salt solu
tion. The aorta specimen shown in FIG. 5 was incu
bated for two hours in a Kreb’s physiological salt solu

track approximately 0.5 X6 mm in dimension.
FIG. 6 depicts the spectral vector in the principal axis
transformation matrix. This corresponds to the spectral
change observed in the artery when the aorta specimen
was incubated in LDL. The major spectral changes
were observed near 1560 nm and between 1700 and
1870 nm.

each wavelength in the analysis, unlike other methods.

FIG. 7 summarizes the process by which the colors
Hence, it should be appreciated that the present method 20 were assigned to pixels in the images. The “O”s repre
is not equivalent to Fourier Transformation (FFT) or
sent sample spectral obtained from the aorta incubated
other data congression techniques like principal compo
without LDL, and the “+”s represent sample spectra
obtained from the aorta incubated in the LDL. The
nents (PCA).
To achieve this end a supercomputer may be utilized
distances are measured in standard deviations (SDs) in
under the direction of appropriate analytical software 25 spectral hyperspace between the center of aorta spec
such as the Best Algorithm software program devel
tral points incubated without LDL and each test speci
oped at the University of Kentucky by Robert A. Lod
men spectral point (the latter point may or may not
der, a co-inventor of the present invention. The Best

come from an aorta specimen incubated in LDL).

Algorithm software program calculates the distance of
A parallel assimilation algorithm, R. A. Lodder, and
the spectrum of each point on the artery wall to the 30 G. M. Hiefije, Appl. Spectrosc, 42, 1351-1365 (1988),
center of the distribution of an ordinary arterial wall.
The user arbitrarily selects colors to denote directions

of spectra in hyperspace, and hence the identity of
chemical constituents. Thus, the direction is. color

was implemented on an IBM 3090-6001 supercomputer
to calculate the distances and assemble the results into
the ?nal color images shown as black and white repre

sentations. The center of the aorta spectral points incu

coded to identify particular chemical species. Addition
ally, the length of the vectors (in standard deviations) is

35 bated without LDL are coded dark blue (DB). Vertical

proportional to the concentration of the chemical spe
cies in the artery wall at the position where the spectra

base-line shifts that likely correlate to vessel wall thick
ness) are coded green (G). Horizontal motions along the
dotted lines shown in FIG. 7 (representing LDL up

were recorded.

motions along the solid lines in FIG. 6 (representing

Thus, the color images are actually color density 40 take) are coded pink (P) and red (R). Red represents a
contour plots whose contours represent the mathemati
larger movement in SDs than pink. The contour lines in
cally determined probability of the tissue having a cer
the aortal images are drawn every 0.1 SD, and a color
change occurs approximately every 3 SDs.
The image shown in FIG. 4 is predominantly blue (B)
a normal artery. As you go more and more SDs from 45 and green (G). This indicates that the aorta specimen is
similar to spectra obtained from such tissues incubated
normal, the probability of being normal (no excess
tain composition. The contours are drawn at set dis

tances in standard deviations (SDs) from the spectra of

LDL) is less. The relationship between SDs and proba
bility can be looked up in a standard table of the Gauss
ian distribution.
All prior art SDs, such as Mahalanobis SDs, are based
on the assumption that spectral clusters are normally

distributed and have radial symmetry (either spheroid
or ellipsoid). In contrast, the SDs of the Best Algorithm
are asymmetrical. In other words, the length of an SD

without LDL. The green (G) portion is caused by a
base-line shift which likely results from a thickening of
the aorta wall which brings the specimen closer to the
optical aperture 23.
The image shown in FIG. 5 shows nearby orthogonal

changes that correspond to the uptake of LDL by the
aorta wall with the red (R) color representing regions of

maximum uptake of LDL. The LDL enters cells intact
is different in one direction than in the opposite direc 55 through receptor-mediated endocytosis (Goodman and
tion. Accordingly, the SDs of the Best Algorithm are
Gilman, “The Pharmacological Basis of Therapeutics”
better suited to handle asymmetrical spectral distribu
8th ed., Pergamon Press, 1990) and remains intact until
catabolism of LDL in cellular lysosomes. The choles
tions in hyperspace such as produced in complex mix
teryl esters are then hydrolyzed, releasing free choles
tures like atheromas.
terol and the amino acids and peptides from the de
EXAMPLE 1
graded lipoprotein are excreted from the cell. The
apolipoprotein are excreted from the cell. The apolipo
False-color “maps” as shown in FIGS. 4 and 5 were
protein B spectrum and amino acids give the peaks
prepared as described below. The FIGS. 4 and 5 show
shown in FIG. 6.
the lipoprotein composition of thoracic aortas obtained
An alternative embodiment 40 of the present inven
from two laboratory rats. The aortas were each excised 65
tion is shown in FIG. 2. In this embodiment 40, the
and partially denuded. This was done by removing the
probe 42 includes a substantially cylindrical shaped
endothelium from a portion of the vessel wall of each
housing 44. The housing 44 is formed with a closed
rate. The aorta specimen shown in FIG. 4 was incu

7
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distal end 46 from any appropriate material including
glass and, more preferably, zirconium ?uoride glass.
A ?ber optic bundle 48 is rigidly mounted and held in
an end cap 50 that seals the proximal end of the housing
44. Preferably, the end cap 50 is also made of glass that
is, for example, heat welded to the sidewall of the cylin

8

completed. This is done as described above in Example

1 by excising and partially denuding a tissue sample
from the endothelium of a portion of a artery or vessel
wall. The excised tissue is incubated and washed. The
tissue is then mounted on a micropositioning stage so

includes seven individual ?ber optic strands. A cen

that it may be carefully analyzed by passing beneath the
optical aperture 23 of the CPC 18.
As discussed above, the CPC 18 focuses simulta
neously and in parallel a limited light spectrum having

drical housing 44.
As best shown in FIG. 3, the ?ber optic bundle 48

trally disposed ?ber optic strand 52 (transmitting ?ber

a wavelength from 1000 to 2500 nm onto a small spot on

optic strand) is operatively connected to a light source
54 (see also FIG. 2). This is the same type of light source

may have a wavelength range from 1500 to 2100 nm.

54 described above with respect to the embodiment

This is because major spectral changes indicating the

the tissue sample T. More preferably, the light spectrum

shown in FIG. 1. Six remaining ?ber optic strands 56a-f
presence of low-density lipoprotein (LDL) may be ob
(receiving ?ber optic strands) are concentrically dis 15 served in this range. In order to determine the presence
posed about the central strand 52. Each of the receiving
of these low-density lipoproteins with analytical preci
strands 56a-f is operatively connected to an individual
sion it is necessary to utilize light across the full spec
light detector 58a-f Once again, any type of detector
trum indicated. This is required as all tissue absorbs
58a-f known in the art to be suitable for the purpose

light at all wavelengths across this range and different

may be utilized (e.g. lead sul?de detectors and liquid 20 tissues absorb only a little more at some wavelengths
nitrogen cooled indium antimonide detectors).
than others. As the particular wavelength(s) where
An inverted, substantially conical re?ector 60 is
these differences occur are not known in advance, it is
mounted in the housing 44 adjacent the distal end 46.
necessary to analyze the entire range with each wave
The re?ector 60 includes a parabolically curved side

wall speci?cally adapted for re?ecting incident light
(note full line action arrows C) outwardly through the
sidewall of the optically pure catheterization housing 44
and focusing that light onto the surface of the arterial

endothelium undergoing in vivo analysis. Scattered
light re?ected from the arterial endothelium is directed
by the substantially ellipsoidal sidewall of the re?ector
60 back into the receiving ?ber optic strands 56a—f (note
dashed line action arrows D).

length being given equal weight in the analysis. Further,
25 this must be done simultaneously and in parallel to in

sure a speed of imaging necessary to make this method

acceptable for clinical applications. Only in this way is
it possible to avoid missing the presence of unusual
tissue of interest to the clinician completing the study.
30 Of course, as indicated above the re?ected light is ana

lyzed using a supercomputer operatively controlled by
appropriate software.
In accordance with a further aspect of the present

This light directing is furthered by having the distal

invention is a method of analyzing arterial endothelium
end of the transmitting ?ber optic strand 52 extend a 35 in vivo utilizing the apparatus shown, for example, in
short distance (between 0.1 and 50.0 mm) beyond the
FIG. 2. In accordance with this method the probe 42 is
distal ends of the receiving ?ber optic strands 56a- as
?rst introduced into an artery. This may be done by any
shown in FIG. 2. More speci?cally light is reflected
known procedure appropriate for this purpose involv
downwardly from the outer sidewall of the transmitting
ing incision and opening of a portion of the artery for
?ber optic strand 52 into the receiving ?ber optic
placement of the catheter probe 42 therein. Procedures
strands 56a-f Further, each of the receiving ?ber optic
similar to those used for the completion of angioplasty
strands 56a-f is effectively shaded from light re?ected
operations may be used for this purpose.
by the arterial endothelium at the opposite side of the
After introducing the probe 42 into the artery, the
artery. Hence, the resulting images are clearer than
probe is manipulated until it is positioned to allow anal
would otherwise be obtainable. The ?ber optic strands 45 ysis of the desired portions of the arterial endothelium.
56a-f direct the re?ected light to the cooperating detec
Once again, this positioning may be completed in accor
tors 56a-f to which the ?ber optic strands are respec
dance with standard techniques utilized in angioplasty

tively operatively connected.

procedures.

As indicated above with respect to the description of
Once the probe 42 has been properly positioned, the
the embodiment shown in FIG. 1, the detectors 58a-f 50 method continues with the step of continuously focus
are operatively connected to a supercomputer 62 that

ing simultaneously and in parallel the near infrared light

provides analysis of the spectra detected by the detec

spectrum of from 1000 to 2500 nm or more preferably
from 1500 to 2100 nm onto the entire area of arterial

tors and produces color images of the arterial endothe
lium. These images may be utilized to determine the
endothelium to be analyzed. Next is the detecting of the
chemical composition of the arterial endothelium and 55 light re?ected by the arterial endothelium by the detec
thus, the chemical makeup of any atherosclerotic le
tors 5811-1‘. Finally, the method concludes with the step
sions and plaques thereon. Advantageously, by deter
of analyzing the spectra detected from the arterial endo

mining the chemical makeup of the lesions and plaques,

thelium and producing color images thereof.

a more effective treatment regimen may be identi?ed
More speci?cally, the full spectrum range of light
and initiated. As a result, the utilization of ineffective 60 originally focused upon the arterial endothelium is de

treatment regimens for the treatment of particular types

tected simultaneously and in parallel and then analyzed

of lesions is avoided. Hence, no time is wasted in treat

simultaneously and in parallel. During the analysis,

ment and more effective and ef?cient treatment is pro

equal weighting is given to each wavelength so as to

vided for the improved safety and health of the patient

insure that any variations in absorbance at any wave

at a lower cost.

In accordance with the method of the present inven
tion, in vitro analysis as described with respect to the
embodiment shown in FIG. 1 may be simply and easily

65 length for each location of tissue undergoing analysis is

observed.

The present method and apparatus thereby provide
spatially resolved chemical analysis resulting in the
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substances such as high density lipoprotein (HDL), low

density lipoprotein (LDL), and apolipoproteins,, such

tissue;
means for detecting light simultaneously and in paral

as apoA-I, apoA-II and apoB, in living arterial tissue. 5
The result is the only known method for high speed
parallel data acquisition and analysis of arterial lesions

lel across a full wavelength range of substantially
1000 to 2500 nm scattered by said tissue; and
means for analyzing the detected light across a full
wavelength range of substantially 1000 to 2500 nm.
said ?ber opticprobe means including a centrally
located light transmitting strand and a radial array

in vivo. Accurate analysis of lesions in vivo is a very
important advance in the art as some types of lesions are
treatable with drugs while others must be removed

surgically. This method allows the lesions to be identi

of light receiving strands concentrically positioned
around said light transmitting strand, said light

?ed by type. Accordingly, unnecessary surgery for
lesion removal is now avoidable. Further, time lost
while undergoing ineffective drug treatments may now
15
be signi?cantly reduced.

transmitting and receiving strands each including a
distal end and said distal end of said light transmit

ting strand projecting beyond said distal ends of
said light receiving strands by between 0.1 and 50.0

FIGS. 8a-c show near infrared spectra of human

apolipoproteins apoA'I, apoA-II and apoB respec

mm.

tively. As should be appreciated, the distinctive spectra

2. The apparatus set forth in claim 1, wherein light

allow the lipoprotein substances to be identi?ed. For
example, apoA-II in HDL has a large, sharp peak near

from said light generating means is of a more limited
wavelength range from substantially 1500 to 2100 nm

2050 nm that is not present in the spectra for apoA-I and

and said means for detecting and analyzing light func

apoB. In contrast, apoB the main apolipoprotein in
LDL has a distinctive, sharp double peak pattern at
approximately 1720 and 1750 nm.

Advantageously, the ability to perform such analysis

10

?ber-optic probe means for transmitting light from
said light generating means to said light directing
means and for receiving light scattered by said

production of color images that allow the doctor or lab
technician to determine the location and quantities of

tions over a more limited wavelength range of substan

tially 1500 to 2100 nm.
25

opens up a large number of possibilities including the
ability to perform kinetic experiments in which the

quantities of these lipoprotein and apolipoprotein sub
stances are studied over time in a lesion. This may be

done both as the lesion grows and/or as various choles
terol-lowering drugs are administered in attempts to
shrink the lesion.
In summary, numerous bene?ts have been described

which result from employing the concepts of the pres 35
ent invention. The apparatus of the present invention
including either of the embodiments shown in FIGS. 1
or 2 may be utilized to effectively and efficiently deter

mine the chemical composition of tissue. The proce
dures may be completed either in vitro or in vivo and

are particularly adapted for determining the chemical
composition and makeup of atherosclerotic lesions as
found on the inner walls of arterial endothelium.

The foregoing description of a preferred embodiment
of the invention has been presented for purposes of 45
illustration and description. It is not intended to be
exhaustive or to limit the invention to the precise form
disclosed. Obvious modi?cations or variations are possi

3. The apparatus set forth in claim 1, wherein said
light directing means is an inverted substantially conical
re?ector.
4. The apparatus set forth in claim 3, wherein said
inverted substantially conical re?ector includes a para

bolic sidewall for scattering incident light and focusing
light re?ected from said tissue.
5. A method of analyzing tissue, comprising the steps
of:

-

focusing simultaneously and in parallel light having a
continuous bandwidth range of at least 600 nm

within a Wavelength range from substantially
l,000—2,500 nm on said tissue to be analyzed;

detecting simultaneously and in parallel light having
said at least 600 nm bandwidth range Within a

wavelength range from substantially l,000—2,500
nm scattered by said tissue; and

analyzing simultaneously and in parallel the detected
light having said at least 600 mm bandwidth range
within a wavelength range from substantially

LOGO-2,500 nm while giving all wavelengths equal

weight.
6. The method set forth in claim 5, wherein said light

ble in light of the above teachings. The embodiment

being focused is of a more limited wavelength range
from substantially 1500 to 2100 nm and said light detect

was chosen and described to provide. the best illustra

ing and analyzing steps are also carried out over a more

tion of the principles of the invention and its practical
application to thereby enable one of ordinary skill in the

limited wavelength range from substantially 1500 to
2100 nm.

art to utilize the invention in various embodiments and
7. A method of analyzing arterial endothelium in vivo
with various modi?cations as is suited to the particular
utilizing a ?ber optic probe, comprising the steps of:
use contemplated. All such modi?cations and variations 55
introducing said probe into an artery;
are within the scope of the invention as determined by
focusing simultaneously and in parallel light having a

the appended claims when interpreted in accordance
with breadth to which they are fairly, legally and equi

tably entitled.
We claim:
1. An apparatus for analyzing tissue including arterial

lesions, comprising:
a light generating means for transmitting simulta
neously and in parallel an incident beam of light
having a wavelength range from substantially 1000 65
to 2500 nm;

means for directing light from said light generating
means onto the tissue to be analyzed;

continuous bandwidth range of at least 600 nm

within a wavelength range from substantially
l,000—2,500 nm on said arterial endothelium to be

analyzed;
detecting simultaneously and in parallel light having
said continuous bandwidth range of at least 600 nm

within a wavelength range from substantially
LOGO-2,500 nm as re?ected by said arterial endo

thelium; and
analyzing simultaneously and in parallel the detected
light having said continuous bandwidth range of at
least 600 nm within a wavelength range from sub

11
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stantially LOGO-2,500 nm while giving all wave

12

and analyzing steps are also carried out over a more

lengths equal weight.

limited wavelength range from substantially 1000 to
8. The method set forth in claim 7, wherein said light
2500
nm.
being focused is of a more limited wavelength range
from substantially 1500 to 2100 nm and said detecting 5
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